Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(14%)

Phase Distribution

Ph early_phase_1
1
14%
Ph phase_1
1
14%
Ph phase_2
5
71%

Phase Distribution

2

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
5(71.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(5)
Terminated(2)

Detailed Status

Completed5
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (14.3%)
Phase 11 (14.3%)
Phase 25 (71.4%)

Trials by Status

terminated114%
completed571%
withdrawn114%

Recent Activity

0 active trials
Showing 5 of 7
withdrawnphase_2

Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer

NCT02077621
completedphase_2

Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients

NCT00860600
completedphase_1

PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy

NCT01696565
terminatedphase_2

Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue

NCT00518869
completedphase_2

PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care

NCT00523107
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT02077621Phase 2

Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer

Withdrawn
NCT00860600Phase 2

Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients

Completed
NCT01696565Phase 1

PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy

Completed
NCT00518869Phase 2

Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue

Terminated
NCT00523107Phase 2

PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care

Completed
NCT01325233Early Phase 1

The Pilot Clinical Study of PG2 Injection on Hemorrhagic Stroke

Completed
NCT01603667Phase 2

PG2 Injection 500 mg in Acute Stroke Study (Pass)

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7